中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

32 records (took 0.025 seconds)

    VETO CELLS GENERATED FROM MEMORY T CELLS
    1.
    发明申请
    VETO CELLS GENERATED FROM MEMORY T CELLS 审中-公开
    记忆T细胞产生的VETO细胞

    公开(公告)号：WO2018002924A1

    公开(公告)日：2018-01-04

    申请号：PCT/IL2017/050716

    申请日：2017-06-27

    Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

    Inventor： REISNER, Yair ,  OR-GEVA, Noga ,  GIDRON BUDOVSKY, Rotem ,  BACHAR-LUSTIG, Esther ,  LASK, Assaf ,  KAGAN, Sivan

    IPC: C12N5/0783 ,  A61K39/00 ,  A61K35/12 ,  A01K67/00

    Abstract: A method of generating an isolated population of non graft versus host disease (GvHD) inducing cells comprising a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) providing a population of at least 70 % memory T cells; (b) contacting the population of memory T cells with an antigen or antigens so as to allow enrichment of antigen reactive cells; and (c) culturing the cells resulting from step (b) in the presence of cytokines so as to allow proliferation of cells comprising the Tcm phenotype. Cells generated by the method, pharmaceutical compositions and methods of treatment are also disclosed.

    Abstract translation: 产生包含中央记忆T淋巴细胞（Tcm）表型的分离的非移植物抗宿主病（GvHD）细胞群的方法，所述细胞为耐受诱导细胞和/或赋予抗 - 疾病活动，并且能够在移植后归巢至淋巴结。 该方法包括：（a）提供至少70％记忆T细胞的群体; （b）使记忆T细胞群体与一种或多种抗原接触以便富集抗原反应性细胞; 和（c）在存在细胞因子的情况下培养步骤（b）产生的细胞，以允许包含Tcm表型的细胞增殖。 还公开了由该方法产生的细胞，药物组合物和治疗方法。

    METHODS OF USING PULMONARY CELLS FOR TRANSPLANTATION AND INDUCTION OF TOLERANCE
    2.
    发明申请
    METHODS OF USING PULMONARY CELLS FOR TRANSPLANTATION AND INDUCTION OF TOLERANCE 审中-公开
    使用肺细胞移植和诱导耐受的方法

    公开(公告)号：WO2017203520A1

    公开(公告)日：2017-11-30

    申请号：PCT/IL2017/050569

    申请日：2017-05-22

    Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

    Inventor： REISNER, Yair ,  HILLEL-KARNIEL, Carmit ,  ROSEN, Chava ,  BACHAR-LUSTIG, Esther ,  SHEZEN, Elias

    IPC: A61K35/42 ,  A61P11/00

    Abstract: A method of treating a pulmonary disorder or injury in a subject in need thereof is disclosed. The method comprising administering to the subject non-syngeneic pulmonary tissue cells in suspension comprising an effective amount of hematopoietic precursor cells (HPCs) or supplemented with HPCs, wherein the effective amount is a sufficient amount to achieve tolerance to the pulmonary tissue cells in the absence of chronic immunosuppressive regimen. A method of inducing donor specific tolerance in a subject in need of a pulmonary cell or tissue transplantation is also disclosed.

    Abstract translation: 公开了一种治疗有需要的受试者的肺部病症或损伤的方法。 所述方法包括向所述对象施用包含有效量的造血前体细胞（HPC）或补充有HPC的悬浮液中的非同基因肺组织细胞，其中所述有效量足以在不存在的情况下实现对肺组织细胞的耐受性 慢性免疫抑制治疗方案。 还公开了在需要肺细胞或组织移植的受试者中诱导供体特异性耐受的方法。

    ANIMAL MODEL FOR HEPATITIS VIRUS INFECTION
    4.
    发明申请
    ANIMAL MODEL FOR HEPATITIS VIRUS INFECTION 审中-公开
    用于感染乙型肝炎病毒的动物模型

    公开(公告)号：WO1994027556A2

    公开(公告)日：1994-12-08

    申请号：PCT/US1994005410

    申请日：1994-05-13

    Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD. ,  DAGAN, Shlomo

    Inventor： YEDA RESEARCH AND DEVELOPMENT CO. LTD. ,  DAGAN, Shlomo ,  REISNER, Yair

    IPC: A61K00/00

    CPC classification number: A61K35/28 ,  A01K67/0271 ,  A61K35/38 ,  A61K35/407 ,  C07K16/109

    Abstract: A non-human chimeric animal useful as a model for human HV infection, comprising a mammal M5 having xenogeneic cells; mammal M5 being derived from a mammal M1 treated to substantially destroy its hematopoietic cells and then transplanted with hematopoietic cells derived from one or more mammals M2 and transplanted with liver tissue from a mammal M3, the one or more mammals M2 and mammal M3 being from the same or from a different species; the transplanted hematopoietic cells from the one or more mammals M2 being either one or both of a hematopoietic cell preparation from a T cell deficient mammal or of a T cell depleted mammalian stem cell or bone marrow preparation; the transplanted liver tissue from mammal M3 being either a human liver tissue preparation or a liver tissue preparation from a non-human mammal capable of being infected by HV; the liver tissue preparation in the M5 mammal being infected by HV.

    Abstract translation: 可用作人HV感染模型的非人嵌合动物，其包含具有异种细胞的哺乳动物M5; 哺乳动物M5衍生自被治疗以基本上破坏其造血细胞并随后从源自一种或多种哺乳动物M2并从哺乳动物M3移植到肝组织的造血细胞移植的哺乳动物M1，一种或多种哺乳动物M2和哺乳动物M3来自 相同或不同的物种; 来自一种或多种哺乳动物M2的移植的造血细胞是来自T细胞缺陷型哺乳动物或T细胞缺失的哺乳动物干细胞或骨髓制剂的造血细胞制剂中的一种或两种; 来自哺乳动物M3的移植的肝组织是人肝组织制剂或能够被HV感染的非人哺乳动物的肝组织制剂; M5哺乳动物的肝组织制剂被HV感染。

    A COMBINATION THERAPY FOR A STABLE AND LONG TERM ENGRAFTMENT
    6.
    发明申请
    A COMBINATION THERAPY FOR A STABLE AND LONG TERM ENGRAFTMENT 审中-公开
    用于稳定和长期整合的组合治疗

    公开(公告)号：WO2013093920A2

    公开(公告)日：2013-06-27

    申请号：PCT/IL2012/050542

    申请日：2012-12-20

    Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

    Inventor： REISNER, Yair ,  BACHAR-LUSTIG, Esther

    IPC: A61K35/18

    CPC classification number: A61K35/28 ,  A61K31/198 ,  A61K31/255 ,  A61K31/661 ,  A61K31/675 ,  A61K31/7076 ,  A61K35/22 ,  A61K35/34 ,  A61K35/36 ,  A61K35/38 ,  A61K35/39 ,  A61K35/407 ,  A61K35/42 ,  A61K39/3955 ,  A61K2035/124 ,  A61K2039/507 ,  A61K2039/515 ,  C12N5/0087 ,  A61K2300/00

    Abstract: A method of treating a subject in need of a non-syngeneic cell or tissue graft is disclosed. The method comprising: (a) transplanting into a subject a dose of T cell depleted immature hematopoietic cells, wherein the T cell depleted immature hematopoietic cells comprise less than 5 x 105 CD3+ T cells per kilogram body weight of the subject, and wherein the dose comprises at least about 5 x 106 CD34+ cells per kilogram body weight of the subject; and subsequently (b) administering to the subject a therapeutically effective amount of cyclophosphamide, wherein the therapeutically effective amount comprises 25-200 mg per kilogram body weight, thereby treating the subject.

    Abstract translation: 公开了一种治疗需要非同基因细胞或组织移植物的受试者的方法。 所述方法包括：（a）向受试者移植剂量的T细胞耗尽的未成熟造血细胞，其中所述T细胞耗尽的未成熟造血细胞每个体重每公斤体重小于5×10 5个CD3 + T细胞，其中所述剂量 包括至少约5×10 6个CD34 +细胞/每公斤体重的受试者; 并且随后（b）向受试者施用治疗有效量的环磷酰胺，其中治疗有效量包含25-200mg /千克体重，从而治疗受试者。

    A COMBINATION THERAPY FOR A STABLE AND LONG TERM ENGRAFTMENT USING SPECIFIC PROTOCOLS FOR T/B CELL DEPLETION
    7.
    发明申请
    A COMBINATION THERAPY FOR A STABLE AND LONG TERM ENGRAFTMENT USING SPECIFIC PROTOCOLS FOR T/B CELL DEPLETION 审中-公开
    使用特定协议对T / B细胞去除的稳定和长期植入的组合治疗

    公开(公告)号：WO2013093919A2

    公开(公告)日：2013-06-27

    申请号：PCT/IL2012/050541

    申请日：2012-12-20

    Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

    Inventor： REISNER, Yair ,  BACHAR-LUSTIG, Esther

    IPC: A61K35/18

    CPC classification number: A61K35/28 ,  A61K31/198 ,  A61K31/255 ,  A61K31/661 ,  A61K31/675 ,  A61K31/7076 ,  A61K35/22 ,  A61K35/34 ,  A61K35/36 ,  A61K35/38 ,  A61K35/39 ,  A61K35/407 ,  A61K35/42 ,  A61K39/3955 ,  A61K2035/124 ,  A61K2039/507 ,  A61K2039/515 ,  C12N5/0087 ,  A61K2300/00

    Abstract: A method of treating a subject in need of a non-syngeneic cell or tissue graft is disclosed. The method comprising: (a) transplanting into a subject a dose of T cell depleted immature hematopoietic cells, wherein the T cell depleted immature hematopoietic cells comprise less than 5 x 105 CD3+ T cells per kilogram body weight of the subject, and wherein the dose comprises at least about 5 x 106 CD34+ cells per kilogram body weight of the subject, and wherein the T cell depleted immature hematopoietic cells are obtained by separating the T cells from the immature hematopoietic cells, by a method comprising: (i) adding an antibody to the immature hematopoietic cells that specifically binds to a surface marker, wherein the antibody is labeled with a magnetically responsive agent; (ii) immobilizing the immature hematopoietic cells specifically bound to the antibody labeled with the magnetically responsive agent in a matrix through a magnetic field; (iii) washing the matrix to remove unbound cells; and (iv) removing the magnetic field to elute bound cells from the matrix; and subsequently (b) administering to the subject a therapeutically effective amount of cyclophosphamide, wherein the therapeutically effective amount comprises 25-200 mg per kilogram body weight, thereby treating the subject.

    Abstract translation: 公开了一种治疗需要非同基因细胞或组织移植物的受试者的方法。 所述方法包括：（a）向受试者移植剂量的T细胞耗尽的未成熟造血细胞，其中所述T细胞耗尽的未成熟造血细胞每个体重每公斤体重小于5×10 5个CD3 + T细胞，其中所述剂量 包括至少约5×10 6个CD34 +细胞/千克体重的受试者，并且其中所述T细胞耗尽的未成熟造血细胞是通过从未成熟的造血细胞中分离T细胞获得的，方法包括：（i） 涉及特异性结合表面标志物的未成熟造血细胞，其中所述抗体用磁性响应剂标记; （ii）通过磁场将特异性结合于用磁响应剂标记的抗体的未成熟造血细胞固定在基质中; （iii）洗涤基质以除去未结合的细胞; 和（iv）去除磁场以从基质中洗脱结合的细胞; 并且随后（b）向受试者施用治疗有效量的环磷酰胺，其中治疗有效量包含25-200mg /千克体重，从而治疗受试者。

    METHODS OF UTILIZING CULTURED HEMATOPOIETIC PROGENITOR CELLS FOR INDUCING IMMUNOLOGICAL TOLERANCE
    8.
    发明申请
    METHODS OF UTILIZING CULTURED HEMATOPOIETIC PROGENITOR CELLS FOR INDUCING IMMUNOLOGICAL TOLERANCE 审中-公开
    利用培养的HEMATOPOIETIC PROGENITOR细胞诱导免疫耐受性的方法

    公开(公告)号：WO2002102971A2

    公开(公告)日：2002-12-27

    申请号：PCT/IL2002/000476

    申请日：2002-06-18

    Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD. ,  REISNER, Yair

    Inventor： REISNER, Yair

    IPC: C12N

    CPC classification number: A61K39/001 ,  A61K39/0008 ,  A61K2035/122 ,  A61K2035/124 ,  A61K2039/515

    Abstract: A method of inducing tolerance to a transplant transplanted from a donor to a recipient is disclosed. The method comprises (a) culturing a hematopoietic progenitor cell (HPC) population under growth conditions suitable for inducing or enhancing veto activity in at least a portion of the HPC population, thereby generating a tolerance-inducing cell population; and (b) administering a dose of the tolerance-inducing cell population prior to, concomitantly with or following transplantation of the transplant, thereby inducing tolerance to the transplant in the recipient.

    Abstract translation: 公开了一种诱导从供体到接受者的移植过程的耐受性的方法。 该方法包括（a）在适于在HPC群体的至少一部分中诱导或增强否决权活性的生长条件下培养造血祖细胞（HPC）群体，从而产生耐受诱导细胞群体; 和（b）在移植之前，伴随或移植后施用一定剂量的耐受诱导细胞群，从而诱导接受者移植的耐受性。

    CONDITIONING PROTOCOLS AND USE OF SAME FOR TISSUE REGENERATION
    10.
    发明申请
    CONDITIONING PROTOCOLS AND USE OF SAME FOR TISSUE REGENERATION 审中-公开
    调理方案和使用相同的组织再生

    公开(公告)号：WO2016203477A1

    公开(公告)日：2016-12-22

    申请号：PCT/IL2016/050638

    申请日：2016-06-16

    Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

    Inventor： REISNER, Yair ,  ROSEN, Chava ,  SHEZEN, Elias ,  MILMAN KRENTSIS, Irit

    IPC: A61K45/00 ,  A61P43/00

    CPC classification number: A61K35/42 ,  A61K9/00 ,  A61K9/0019 ,  A61K31/015 ,  A61K31/255 ,  A61K31/675 ,  A61K35/12 ,  A61K35/28 ,  A61K45/06 ,  A61N5/10 ,  C12N5/00 ,  A61K2300/00

    Abstract: A method of conditioning a subject in need of transplantation of progenitor cells in suspension of a tissue of interest is disclosed. The method comprising: (a) administering to a subject a therapeutically effective amount of an agent capable of inducing damage to the tissue of interest, wherein the damage results in proliferation of resident stem cells in the tissue; and subsequently (b) subjecting the subject to an agent which ablates the resident stem cells in the tissue. A method of transplanting progenitor cells in suspension of a tissue of interest to a subject in need thereof is also disclosed.

    Abstract translation: 公开了一种调节需要移植祖细胞悬浮于感兴趣组织的受试者的方法。 所述方法包括：（a）向受试者施用治疗有效量的能够诱导所述感兴趣组织损伤的药剂，其中所述损伤导致组织中常驻干细胞的增殖; 并且随后（b）使受试者接受消融组织中常驻干细胞的药剂。 还公开了将有兴趣的组织悬浮的祖细胞移植到有需要的受试者的方法。

Patent Agency Ranking